“drugs” Archives

in
Entry Author Date Location
Pivoting Again, Catabasis Looks to NASH After Cholesterol Drug Flops 06/07/16 Boston
Biogen’s Nerve Repair Drug Fails MS Study, Shares Fall 06/07/16 Boston
Ocular’s Shares Fall After Eye Treatment Fails Latest Test 06/06/16 Boston
Nektar Therapeutics Gets $20M in Daiichi Deal For Breast Cancer Drug 06/01/16 San Francisco
Two Years After Paying $680M, BioMarin Shelves Duchenne Drug 05/31/16 San Francisco
Amicus Nabs First Approval as EU Gives Green Light to Fabry Drug 05/31/16 New York
Celator Parlays Leukemia Drug Data into $1.5B Buyout From Jazz Pharma 05/31/16 New York
Minerva’s Shares Soar on Early Data for Schizophrenia Drug 05/26/16 Boston
After Failed Trial, Forum CEO Dunsire Leaves, Company’s Fate Unclear 05/25/16 Boston
Spero Rolls up More Antibiotics With Vertex Deal 05/25/16 Boston
Sarepta Saga Drags On as FDA Delays Decision on Duchenne Drug 05/25/16 Boston
Sophiris Streamlines Operations, Weighs Options on Prostate Drug 05/25/16 San Diego
Retooled Selecta Bio Takes Crossover Cash to IPO Queue 05/24/16 Boston
Arbor Pharma Pays $467M for Struggling XenoPort, Restless Legs Drug 05/23/16 San Francisco
Four Years After Neuronex Buyout, Acorda Dumps Epilepsy Drug 05/20/16 New York
CPRIT Marks Midpoint in Texas Agency’s 10-Year Cancer-Fighting Mandate 05/18/16 Texas
Agios, Celgene Jump into Immuno-Oncology in Revamped Alliance 05/17/16 Boston
Pfizer, Moving on From Allergan, Pays $5.2B For Anacor Pharma 05/16/16 San Francisco
Houston’s Adhesys Medical Forms Partnership with German Pharma Firm 05/12/16 Texas
Ariad Sells Off Europe Hub, Drug Rights in $140M Incyte Deal 05/09/16 Boston
More than a Matter of Appearances: Pharma’s Existential PR Problem 05/05/16 San Diego
A Vision for Boosting the Life Sciences in San Diego and Beyond 05/04/16 San Diego
Sharpening Neuro Focus, Biogen to Spin Out Hemophilia Biz 05/03/16 Boston
Pressured by a Lender, Bind Files for Bankruptcy 05/02/16 Boston
In M&A Bonanza, AbbVie, Sanofi Throw Billions at Stemcentrx, Medivation 04/28/16 San Francisco
Texas Roundup: Rapamycin, SparkCognition, MolecularMatch, Rackspace 04/27/16 Texas
Near-Term FDA Nod Unlikely For Duchenne Drug After Negative Vote 04/25/16 Boston
Houston’s MolecularMatch Expands Cancer Patient Treatment Service 04/25/16 Texas
Chiasma Shares Crater as FDA Rejects Hormone Drug, Asks For More Data 04/18/16 Boston
San Diego Venture Funding Drops in QI—But Here are Top 10 Deals 04/18/16 San Diego
Page 2 of 89 « previous page · next page »